Results · Apr-Jun 2026 · filed 21 Sep 2026
Symbiotec Pharmalab Q1 FY27 results
Sales grew 3% to ₹211 crore from ₹204 crore in Apr-Jun 2025.
Operating profit was ₹59.2 crore, an operating margin of 28.1%.
Net profit grew 6% to ₹47 crore from ₹44.5 crore in Apr-Jun 2025.
Apr-Jun 2026 vs a year ago
| ₹ crore | Apr-Jun 2026 | Apr-Jun 2025 | Change |
|---|---|---|---|
| Sales | 210.8 | 204.3 | +3% |
| Operating profit (EBITDA) | 59.2 | - | - |
| Operating margin | 28.1% | - | - |
| Net profit | 47.0 | 44.5 | +6% |
Standalone figures. Margins & ratios change in percentage points (pts).
The earnings call
Symbiotec Pharmalab reported Apr–Jun 2026 consolidated revenue of ₹218 crore (7% growth from a year earlier) with API business at ₹215 crore & gross margins above 60%. Management targets 20-25% revenue & EBITDA growth for FY27, with new CDMO & complex injectables businesses expected to generate multi-million dollar milestone revenues in Oct 2026 to Mar 2027.
The last 2 quarters
Filings that week
- 22 Sep 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
- 22 Sep 2026Announcement under Regulation 30 (LODR)-Newspaper Publication
- 21 Sep 2026Announcement under Regulation 30 (LODR)-Press Release / Media Release
- 21 Sep 2026Announcement under Regulation 30 (LODR)-Investor Presentation
- 21 Sep 2026Results - Financials For Quarter Ended Jun 30, 2026
- 21 Sep 2026Board Meeting Outcome for Outcome Of The Board Meeting Of The Company Held On Monday, September 21, 2026
From the company's results filed on BSE (Standalone). Business numbers only. Education & analysis, not investment advice or a recommendation.